Archive

Filter

Amgen (AMGN) is well-positioned for the aging population with its osteoporosis drug Prolia ($1.5 billion in annual sales) and has the potential to increase its market share in the treatment of the condition with Romosozumab, a related drug aimed at spinal vertebral fractures in patients with osteoporosis. Romosozumab is currently… Read More

Thank you for joining us on what we believe will be an epic journey. At the risk of sounding immodest, this inaugural issue of Breakthrough Tech Profits represents a new era in tech investing that will go far beyond the traditional boundaries of the information technology sector.Although a lot of… Read More

Shares of Novo Nordisk (NVO) rallied on May 25th after the U.S. Food and Drug Administration (FDA) approved the combination drug IdegLira for the treatment of type II Diabetes.  The drug combines two of Novo’s previously existing drugs; Tresiba, (insulin degludec) along with its GLP-1 agonist, Victoza (liraglutide) showed in clinical… Read More

For the reasons explained in our special report, “Three Hot Stocks for the $150 Billion Virtual Reality Revolution“, we are opening new positions in HiMax Technologies (HIMX), Immersion Corporation (IMMR) and Microvision Inc. (MVIS). More information on these three companies, including buy limit and support level pricing data, can be found… Read More